|
Market Closed -
Other stock markets
|
After hours 22:59:59 | |||
| 0.6980 EUR | +36.59% |
|
0.6910 | -1.00% |
| 07-13 | AB Science to Discontinue Three Masitinib-related Clinical Studies | MT |
| 07-10 | AB Science streamlines its portfolio and refocuses on two molecules |  |
Company Valuation: AB Science
Data adjusted to current consolidation scope
| Fiscal Period: December | 2022 | 2023 | 2024 | 2025 | 2026 | 2027 | 2028 |
|---|---|---|---|---|---|---|---|
| Market Cap 1 | 332.2 | 180.9 | 57.55 | 112 | 55.85 | - | - |
| Change | - | -45.55% | -68.19% | 94.7% | -50.15% | - | - |
| Enterprise Value (EV) | 332.2 | 180.9 | 57.55 | 112 | 55.85 | 55.85 | 55.85 |
| Change | - | -45.55% | -68.19% | 94.7% | -50.15% | 0% | 0% |
| P/E | -24.4x | -17.8x | -5.88x | - | - | - | - |
| PBR | - | - | - | - | - | - | - |
| PEG | - | 0.6x | 0.2x | - | - | - | - |
| Capitalization / Revenue | - | 187x | 53.7x | 95.4x | 46.5x | 43x | 34.9x |
| EV / Revenue | - | 0x | 0x | 0x | 46.5x | 43x | 34.9x |
| EV / EBITDA | - | - | - | - | - | - | - |
| EV / EBIT | - | -0x | -0x | 0x | -8.59x | -8.73x | - |
| EV / FCF | - | -0x | - | -0x | -8.73x | -15.5x | -14.3x |
| FCF Yield | - | -9.52% | - | -4.08% | -11.5% | -6.45% | -6.98% |
| Dividend per Share 2 | - | - | - | - | - | - | - |
| Rate of return | - | - | - | - | - | - | - |
| EPS 2 | -0.29 | -0.2 | -0.15 | - | - | - | - |
| Distribution rate | - | - | - | - | - | - | - |
| Net sales 1 | - | 0.97 | 1.072 | 1.174 | 1.2 | 1.3 | 1.6 |
| EBITDA | - | -11.16 | -5.416 | - | - | - | - |
| EBIT 1 | - | -13.43 | -6.083 | 0.639 | -6.5 | -6.4 | - |
| Net income | -13.62 | -10.05 | -7.831 | - | - | - | - |
| Net Debt | - | - | - | - | - | - | - |
| Reference price 2 | 7.0900 | 3.5550 | 0.8820 | 1.5360 | 0.5110 | 0.5110 | 0.5110 |
| Nbr of stocks (in thousands) | 46,861 | 50,891 | 65,248 | 72,947 | 80,015 | - | - |
| Announcement Date | 3/1/23 A | 5/15/24 A | 5/13/25 A | 5/13/26 A | - | - | - |
1EUR in Million2EUR
Estimates
P/E, Detailed evolution
| P/E (Y) | EV / Sales (Y) | EV / EBITDA (Y) | Dividend Yield (Y) | Capi.($) | ||
|---|---|---|---|---|---|---|
 | - | - | - | - | 46.55M | |
| 38.22x | 5.4x | 20.88x | 2.59% | 324B | |
| 23.55x | 3.23x | 11.51x | 1.68% | 68.88B | |
| 12.28x | 6.25x | 9.52x | - | 9.72B | |
| 16.95x | 2.16x | 7.38x | 2.63% | 8.37B | |
| 21.5x | 6.1x | 17.23x | -.--% | 4.32B | |
| 41.13x | 2.36x | 29.57x | 0.74% | 3.83B | |
| 31.19x | 5.93x | 16.97x | - | 3.62B | |
| 103.82x | - | - | -.--% | 2.68B | |
| Average | 36.08x | 4.49x | 16.15x | 1.27% | 47.24B | |
| Weighted average by Cap. | 35.04x | 4.99x | 18.83x | 2.38% |
Y-o-Y evolution of P/E
Historical PBR trend
Evolution Enterprise Value / Sales
Change in Enterprise Value/EBITDA
- Stock Market
- Stocks
- AB Stock
- Valuation AB Science
Select your edition
All financial news and data tailored to specific country editions
